About us Contacts Drug interactions: 390 212
Drug search by name

Incobotulinumtoxina Intramuscular and Plazomicin Intravenous

Determining the interaction of Incobotulinumtoxina Intramuscular and Plazomicin Intravenous and the possibility of their joint administration.

Check result:
Incobotulinumtoxina Intramuscular <> Plazomicin Intravenous
Relevance: 01.09.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using incobotulinumtoxinA together with plazomicin may increase the risk of certain side effects such as excessive muscle weakness, paralysis, and difficulty breathing, swallowing, or speaking. In rare cases, swallowing and breathing difficulties may be life-threatening or fatal. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR CLOSELY: The effects of botulinum toxin may be potentiated by neuromuscular blockers, aminoglycoside antibiotics, and other drugs that can interfere with neuromuscular transmission. Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive neuromuscular blocking effects may occur when these agents are used together.

MANAGEMENT: Caution is advised when botulinum toxin is used in combination with neuromuscular blockers, aminoglycoside antibiotics, or other drugs that can interfere with neuromuscular transmission. These drugs should be avoided in patients suspected of having botulinum toxin overdose or poisoning. Because the effects of botulinum toxin products may spread from the area of injection, patients should be monitored closely for adverse effects such as asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties, which can occur hours to weeks after injection. Swallowing and breathing difficulties may be life-threatening or fatal. Patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders such as myasthenia gravis or Lambert-Eaton syndrome may be particularly susceptible.

References
  • "Product Information. Myobloc (botulinum toxin type B)" Elan Pharmaceuticals, S. San Francisco, CA.
  • "Product Information. Xeomin (botulinum toxin type A (obsolete) (botulinum toxin type A))." Merz Pharmaceuticals, Greensboro, NC.
  • "Product Information. Dysport (abobotulinumtoxinA)." Tercica Inc, Brisbane, CA.
  • "Product Information. Botox (onabotulinumtoxin A)." Allergan Inc, Irvine, CA.
Incobotulinumtoxina Intramuscular

Generic Name: incobotulinumtoxinA

Brand name: Xeomin

Synonyms: Incobotulinumtoxina (Intramuscular)

Plazomicin Intravenous

Generic Name: plazomicin

Brand name: Zemdri

Synonyms: Plazomicin

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.